Affiliation:
1. Universidade Estadual de Campinas
Abstract
RATIONALE: Metabolic acidosis induced by topiramate is a well documented but infrequent adverse event. The objective was to demonstrate the lowering of carbon dioxide serum levels, which is usually asymptomatic but may facilitate the occurrence of metabolic acidosis in patients using topiramate. METHODS: We evaluated, prospectively, the carbon dioxide serum levels of 18 patients seen at the epilepsy clinic of our university hospital, before and 3 months after introducing topiramate. RESULTS: Five patients were female and 13 were male, age ranging from 2 to 16 years old (mean=9.3). Carbon dioxide mean serum levels were 25 and 21.2 mmol/L (normal = 22 to 30), before and 3 months after introducing topiramate, respectively. Dose ranged from 2.08 to 11.76 mg/kg/day (mean=6.7mg/kg/day). Adverse events were anorexia, nausea and somnolence. CONCLUSION: We conclude that the lowering of carbon dioxide serum levels induced by topiramate is mostly asymptomatic, but may facilitate the occurrence of metabolic acidosis. Since patients in use of topiramate have refractory epilepsy, they may need epilepsy surgery, and must be carefully monitored for the risk of metabolic acidosis during surgery.
Subject
Neurology,Clinical Neurology
Reference11 articles.
1. The treatment of epilepsy;Reife RA,1996
2. Topiramate and metabolic acidosis;Wilner A;Epilepsia,1999
3. Acute mental status changes and hyperchloremic metabolic acidosis with long-term topiramate therapy;Stowe CD;Pharmacotherapy,2000
4. Topiramate and metabolic acidosis in pediatric epilepsy;Takeoka M;Epilepsia,1999
5. Efficacy and safety of topiramate in refractory epilepsy: a long-term prospective study;Tartara A;Ital J Neurol Sci,1996
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献